SCHEMBL6994066

SCHEMBL6994066

CCOC(=O)c1c(Nc2ccccc2N)sc2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.54
CDC25B P30305 5/20 0.51
MAPK1 P28482 2/20 0.48
TSHR P16473 1/20 0.48
MAPT P10636 5/20 0.46
ALDH1A1 P00352 5/20 0.45
HSD17B10 Q99714 1/20 0.45
LMNA P02545 3/20 0.44
ALOX12 P18054 1/20 0.44
NPC1 O15118 1/20 0.43
NFKB1 P19838 1/20 0.43
RAB9A P51151 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
KMT2A Q03164 2/20 0.43
GABRP O00591 1/20 0.43
GABRD O14764 1/20 0.43
GABRA1 P14867 1/20 0.43
GABRB1 P18505 1/20 0.43
GABRG2 P18507 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6992504 0.89 SMN1; SMN2 (0.55) SMN1; SMN2CDC25BMAPK1TSHRMAPT
SCHEMBL6998866 0.89 CISD2 (0.45) SMN1; SMN2CDC25BMAPK1TSHRMAPT
SCHEMBL6996750 0.89 SMN1; SMN2 (0.45) SMN1; SMN2CDC25BMAPK1TSHRMAPT
SCHEMBL6993864 0.87 SMN1; SMN2 (0.43) SMN1; SMN2CDC25BMAPK1TSHRMAPT
SCHEMBL6991553 0.87 SMN1; SMN2 (0.43) SMN1; SMN2CDC25BMAPK1TSHRMAPT
SCHEMBL6996720 0.87 MAPT (0.44) SMN1; SMN2CDC25BMAPK1TSHRMAPT
SCHEMBL6997282 0.87 SMN1; SMN2 (0.51) SMN1; SMN2CDC25BMAPK1TSHRMAPT
SCHEMBL6997271 0.87 MAPT (0.44) SMN1; SMN2CDC25BMAPK1TSHRMAPT
SCHEMBL6999000 0.87 IDO1 (0.44) SMN1; SMN2CDC25BMAPK1TSHRMAPT
SCHEMBL7000437 0.87 SMN1; SMN2 (0.43) SMN1; SMN2CDC25BMAPK1TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT SMN1; SMN2 1349/4885CDC25B 240/4885MAPK1 1616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.